KoBioLabs said on Friday that it has been selected as a research institute of the Ministry of Trade Industry and Energy’s (MOTIE) Bio-Industry Technology Development Project to commercialize a microbiome therapeutic for treating severe autism spectrum disorders (ASD).The project aims to develop huma
A recently published study by the Karolinska Institute suggests that vaccines against smallpox given until the mid-1970s offer continuing cross-reactive immunity to mpox, previously known as monkeypox.Recently, the World Health Organization (WHO) lifted the Public Health Emergency of International C
DIGMBIO said on Friday that it signed a business agreement with Inno Pharma Screen (IPS) to develop KRAS anti-cancer drugs using molecular glue technology.DIGMBIO will apply the molecular glue technology from IPS in a joint development project to target intractable KRAS G12D-mutated pancreatic and c
Hanmi Pharm said it has made a poster presentation on the results of its study of efocipegtrutide, HM15211, at the ATS (American Thoracic Society) 2023 in Washington, D.C., on May 19 to 24 (local time).Efocipegtrutide is a LAPSTriple agonist applied by Hanmi's platform technology, “LAPScovery,” whic
Celltrion said on Friday it filed a marketing authorization application with the European Medicines Agency (EMA) for CT-P43, a biosimilar referencing Stelara (ingredient: ustekinumab) to treat autoimmune diseases.Stelara, the original drug, is an interleukin (IL)-12 and 23 inhibitor developed by Jan
Hanmi Pharm's Rosuz, a new combination drug treating dyslipidemia, has shown greater clinical usefulness than high-intensity statin monotherapy in a series of studies published in international journals.Hanmi said Thursday that “eClinicalMedicine,” a sister publication of the international medical j
Samyang Holdings Corp. said it has signed a partnership agreement with Hangzhou Yxintent, a Chinese medical device and aesthetics company, for the export of Lafullen, a polycaprolactone (PCL)‐based filler.Lafullen is a filler for facial plastic surgery developed by Samyang Holdings. It is composed o
HanAll Biopharma and Daewoong Pharmaceutical said that they have entered into a joint research and development agreement with Boston-based preclinical biopharmaceutical company NurrOn Pharmaceuticals to develop treatments for Parkinson's disease and other neurodegenerative diseases.Under the agreeme
Genome&Company said on Wednesday that it published a study showing that intracellular adhesion molecule-1 (ICAM-1), an immunomodulator, improves the responsiveness of immune regulatory proteins by activating CD8+ T Cells.The research team, led by Genome&Company CEO Park Han-soo who also serves as a
BMS Korea said on Wednesday that Camzyos (ingredient: mavacamten), an obstructive hypertrophic cardiomyopathy (oHCM) treatment, won approval from the Ministry of Food and Drug Safety (MFDS).Camzyos is indicated for the improvement of exercise function and symptoms in adult patients with symptomatic
For nearly 30 years, Roche has diligently carried out its global research and development (R&D) initiatives in Korea since the establishment of its clinical division in 1997. Korea has emerged as a pivotal strategic destination for Roche's R&D operations, hosting an impressive 40 percent of the comp
Celltrion said on Wednesday that its Humira biosimilar, Yuflyma (ingredient: adalimumab) a biosimilar to treat autoimmune diseases, obtained marketing approval from the U.S. FDA.With this approval, Yuflyma will be available in the U.S. in July for key indications covered by the original drug Humira
In Korea, pneumococcal serotype “19A” is commonly found in infants under five to adults over 65. However, serotype “3” is more prominently observed in adults, according to a study.“Korea’s serotype distribution is completely different from that of other countries, such as the U.S., France, and Japan
Competition in the Korean shingles vaccine market has reignited this year with the launch of GSK's Shingrix.According to IQVIA, a drug market research firm, the local shingles vaccine market grew from 10.5 billion won ($8 million) in the fourth quarter of last year to 21.8 billion won in the first q
Two Korean-made treatments, Rolvedon by Hanmi Pharm for neutropenia and Xcopri by SK Biopharmaceuticals for epilepsy, have shown significant sales growth in the first quarter in the U.S.According to Hanmi, Rolvedon posted sales of $15.62 million (20.8 billion won) in the U.S. in the first three mont
The first real-world data (RWD) for Yuhan Corp.’s new lung cancer treatment Leclaza (lazertinib) in the second-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in Korea has been released. The research team, led by Professor Lim Sun-min at the Oncology Division of Yonsei Ca
Exkivity (mobocertinib), Takeda’s targeted agent for EGFR (epidermal growth factor receptor) Exon 20 insertion mutation non-small cell lung cancer (NSCLC), will likely improve patients’ quality of life, too, an expert predicted.Professor Kim Tae-min of the Hemato-Oncology Department at Seoul Nationa
Merz Aesthetics said it recently held the "Confidence To Be" festival at COEX, Seoul, on May 13.According to the company, the festival was designed to directly communicate the meaning of Merz's global "Confidence To Be" campaign to Korean consumers, offering them the opportunity to experience a vari
Amid the rapid growth of type-2 diabetes drugs, Daewoong Pharmaceutical has set a goal to increase the sale of its SGLT-2 inhibitor, Envlo (enavogliflozin), to 100 billion won ($76 million) within three years.Daewoong is determined to grow the 36th homegrown new drug and SGLT 2 (sodium-glucose cotra
Heart failure patients with an ejection fraction rate of greater than 40 percent can use Entresto (sacubitril/valsartan) regardless of the chronicity of the disease or treatment environment, a recent study has shown.Dr. Robert Mentz of Duke University Medical Center unveiled the result of the PARAGL